Sign inJoin waitlistJoin the waitlist

David Jackman

Medical Director of Clinical Pathways and New Business Initiatives, Dana-Farber Cancer Institute · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present
Mass General Brigham
Present

Dana-Farber Cancer Institute
2003–2005
Internal Medicine
Beth Israel Deaconess Medical Center
2000–2003
Alpert Medical School
1996–2000

Research

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2015 · 962 citations
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
Journal of Clinical Oncology · 2010 · First of 9 authors · 682 citations
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Clinical Cancer Research · 2014 · 658 citations

Pasi Jänne
32 papers
BJ
Bruce Johnson
29 papers
Lecia Sequist
12 papers · 1 as a fellow
MR
Michael Rabin
12 papers
Hiroto Hatabu
10 papers
Geoffrey Oxnard
9 papers
SC
Stephanie Cardarella
9 papers · 1 as a fellow
Daniel Costa
8 papers
NL
Neal Lindeman
8 papers
Mohit Butaney
7 papers
Lynette Sholl
6 papers · 1 as a fellow
Elizabeth Baldini
5 papers

Clinical trials

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
David M. Jackman, MD
2010–2016
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2010–2014
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Principal investigator · Completed · Phase 2
David M. Jackman, MD
2010–2017